Mineralys Therapeutics CMO Sells Shares
Rodman David Malcom sold 4,584 shares of Mineralys Therapeutics, Inc. on June 17, 2026.
Key Points
- Rodman David Malcom, the Chief Medical Officer of Mineralys Therapeutics, sold 4,584 shares for $114,600 on June 17, 2026.
- Shares of Mineralys Therapeutics, Inc. traded at approximately $23.99, with a market cap of about $2.11 billion.
- Several analysts maintain a buy rating for Mineralys Therapeutics, with price targets ranging up to $56.
On June 17, 2026, Rodman David Malcom, the Chief Medical Officer at Mineralys Therapeutics, Inc. (NasdaqGS: MLYS), sold 4,584 shares of the company. This planned transaction was executed at an average price of $25.00 per share, totaling approximately $114,600.
Other Institutional Activity in Mineralys Therapeutics
Catalys Pacific, LLC maintained its position in Mineralys Therapeutics with 7,903,838 shares valued at about $214.1 million. Meanwhile, RA Capital Management, L.P. increased its holdings by 369,000 shares, bringing its total to 7,692,750 shares worth approximately $208.4 million. Samsara BioCapital, LLC held steady with 5,871,018 shares valued at $159.0 million. FMR LLC reduced its position by 196,405 shares, leaving it with 4,861,104 shares worth $131.7 million. BlackRock, Inc. added 153,904 shares, resulting in a total of 4,481,582 shares valued at $121.4 million.
Mineralys Therapeutics Stock Snapshot
Shares of Mineralys Therapeutics, Inc. (NasdaqGS: MLYS) traded around $23.99. The company has a market capitalization of approximately $2.11 billion. Mineralys is currently not profitable, reflected by its forward P/E ratio of -11.44. The stock's 52-week range spans from $12.59 to $47.65, with a 50-day moving average of $27.72 and a 200-day moving average of $33.07. The current ratio stands at 44.33, indicating strong liquidity.
Analysts Set New Price Targets
Analysts have shown strong support for Mineralys Therapeutics. On March 13, 2026, B of A Securities maintained a buy rating with a price target of $51.0. Other firms like Stifel and HC Wainwright & Co. have also upheld buy ratings with targets of $52.0 and $56.0, respectively. The consensus among analysts remains a strong buy, with a mean target price of $49.0 based on eight analyst opinions.
About Mineralys Therapeutics
Mineralys Therapeutics, Inc. is a biopharmaceutical company based in Radnor, Pennsylvania. It focuses on developing medicines targeting diseases caused by dysregulated aldosterone, such as hypertension and chronic kidney disease. The company's lead product, lorundrostat, is an orally administered aldosterone synthase inhibitor. Mineralys, led by CEO Dr. Jon Congleton, was incorporated in 2019 and employs around 76 people.
Bottom Line
Insider transactions, like the recent planned sale by Rodman David Malcom, provide insight into company leadership's actions and potential outlook. Mineralys Therapeutics is a developing player in the biotechnology field, with strong institutional interest and positive analyst ratings. As always, investors should remember that insider sales do not necessarily indicate negative sentiment, and 13F filings offer a historical view of institutional positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.